Mostrando 10 resultados de: 51
Filtros aplicados
Publisher
Pharmacogenomics Journal(9)
Pharmacogenomics(8)
Molecular Psychiatry(4)
Schizophrenia Research(3)
Drug Metabolism and Drug Interactions(2)
Área temáticas
Farmacología y terapéutica(21)
Problemas sociales y servicios a grupos(10)
Medicina y salud(7)
Bioquímica(6)
Psicología diferencial y del desarrollo(6)
Origen
scopus(51)
Clinical implementation of pharmacogenetics and personalized drug prescription based on e-health: The MedeA initiative
ArticleAbstract:Palabras claves:Autores:Adrián LLerena, Cobaleda J., de Andrés F., Mata-Martín C., Penãs-Lledó E.M., Pijierro A., Sánchez C.L.Fuentes:scopusClinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusClinical use of pre-emptive pharmacogenetic programmes
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Penãs-Lledó E.M.Fuentes:scopusCognitive behaviour therapy response and dropout rate across purging and nonpurging bulimia nervosa and binge eating disorder: DSM-5 implications
ArticleAbstract: Background: With the imminent publication of the new edition of the Diagnostic and Statistical ManuaPalabras claves:Binge eating disorder (BED), Bulimia nervosa (BN), classification, Cognitive-behavioural therapy (CBT), DSM-5Autores:Agüera Z., Arcelus J., Fernández‐aranda F., Islam M.A., Menchón J.M., Murcia S.J., Penãs-Lledó E.M., Riesco N., Roser Granero, Sánchez‐díaz I., Vicente E.Fuentes:scopusAssociation between T102C and A-1438G polymorphisms in the serotonin receptor 2A (5-HT2A) gene and schizophrenia: Relevance for treatment with antipsychotic drugs
ArticleAbstract: Background: An involvement of serotonin receptor 2A (5-HT2A) in the aetiology of schizophrenia has bPalabras claves:A-1438G polymorphism, Risperidone, Schizophrenia, Seretonin 2A receptor, T102C polymorphismAutores:Adrián LLerena, Cáceres M.C., De la Rubia A., Dorado P., Penãs-Lledó E.M.Fuentes:scopusAntipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
ReviewAbstract: Although the most common, and usually serious, side effects of first-generation (or typical) antipsyPalabras claves:Antipsychotic drugs, Cardiac side effects, CYP2D6, drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmiaAutores:Adrián LLerena, Berecz R., Dorado P., Penãs-Lledó E.M.Fuentes:scopusA combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances
ArticleAbstract: This study examined, for the first time, whether a high CYP2D6-CYP2C19 metabolic capacity combinatioPalabras claves:Autores:Adrián LLerena, Blasco-Fontecilla H., Courtet P., Delgado A., Guillaume S., Jaussent I., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusA one-year follow-up study of treatment-compliant suicide attempt survivors: relationship of CYP2D6-CYP2C19 and polypharmacy with suicide reattempts
ArticleAbstract: This study of a cohort of 1-year treatment-compliant survivors of a suicide attempt examined for thePalabras claves:Autores:Adrián LLerena, Cortés-Martínez A., Courtet P., de Andrés F., Dubois J., Guillaume S., Kahn J.P., Leboyer M., Olié E., Penãs-Lledó E.M.Fuentes:scopusABCB1 gene polymorphisms and violent suicide attempt among survivors
ArticleAbstract: Introduction: Those suicide attempters that choose violent methods dramatically diminish the possibiPalabras claves:ABCB1, Suicide attempt, Violent suicide methodsAutores:Adrián LLerena, Courtet P., Delgado A., Guillaume S., Jaussent I., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2C9 gene and susceptibility to major depressive disorder
ArticleAbstract: Alteration of monoaminergic neurotransmission has been implicated in the pathophysiology of mood disPalabras claves:CYP2C9 gene, Depression, SchizophreniaAutores:Adrián LLerena, Berecz R., De la Rubia A., Dorado P., González A.P., Penãs-Lledó E.M.Fuentes:scopus